胆固醇酯转移蛋白抑制剂的研究进展  

Research progress on cholesterol ester transfer protein inhibitors

作　　者：饶甲环 马煜盛 龙洁旎 郭志刚[1] RAO Jia-huan;MA Yu-sheng;LONG Jie-ni(reviewing);GUO Zhi-gang(checking)(Department of Cardiology,Huiqiao Medical Center,Nanfang Hospital,Southern Medical University,Guangzhou 510515,Guangdong,China)

机构地区：[1]南方医科大学南方医院惠侨医疗中心心血管病区

出　　处：《医学研究生学报》2019年第7期776-779,共4页Journal of Medical Postgraduates

基　　金：广东省普通高校省级重大科研项目(2016KZDXM016)

摘　　要：多年来,人们对胆固醇酯转移蛋白(CETP)抑制剂的研究不曾中断,欲在他汀降低LDL-C的基础上提高HDL-C水平,从而进一步获得心血管保护作用。然而,以Torcetrapib为代表的CETP抑制剂大型临床研究的失败令这一研究领域争议不断。2017年欧洲心脏病学会年会,公布了关于Anacetrapib的3期临床研究的结果,使得CETP抑制剂重新获得了极大关注。文章主要对4种CETP抑制剂的研发历程,临床效应及其差异所在进行综述。For many years, studies on cholesteryl ester transfer protein inhibitors(CETP) have not been interrupted, intending to achieve further cardiovascular protection through increasing the level of HDL-C on the basis of statin-lowering LDL-C. However, the failure of large clinical studies of CETP inhibitors represented by torcetrapib has caused continuous controversy in this area of research. The 2017 European Society of Cardiology Annual Conference published the results of Phase 3 clinical trials on Anacetrapib, which regained significant attention to CETP inhibitors. Based on these, this article reviewed the development of the four major CETP inhibitors, and briefly discusses their clinical effects and differences.

关 键 词：胆固醇酯转移蛋白 动脉硬化性心血管疾病 主要心血管不良事件 

分 类 号：R543[医药卫生—心血管疾病]